In recent years, Glucagon-like peptide-1 (GLP-1) receptor agonists have transformed the landscape of medical weight loss. Originally developed to treat type 2 diabetes, these medications are now widely recognized for their efficacy in managing obesity. At Kenilworth Primary Care, Bhavani Jeereddy, MD, specializes in clinical lipidology and internal medicine, helping patients in Kenilworth, NJ, understand the biological mechanisms that make these treatments so effective.
The primary way GLP-1 medications facilitate weight loss is by mimicking a natural hormone produced in the intestines. When you eat, your body releases GLP-1 to signal to the brain that you are full. In many individuals struggling with chronic weight issues, this signaling pathway may be less sensitive.
GLP-1 receptor agonists target the centers of the brain that regulate appetite and food intake. By binding to these receptors, the medication increases feelings of satiety and decreases hunger cravings. This biological "nudge" makes it significantly easier for patients to adhere to a reduced-calorie diet without the constant physical sensation of hunger.
Beyond the brain, GLP-1 medications act directly on the digestive system. They slow down the rate at which the stomach empties its contents into the small intestine, a process known as gastric emptying. When food stays in the stomach longer, you feel full for a more extended period after a meal.
Healthline notes that this delayed emptying prevents the rapid spikes in blood sugar that often lead to energy crashes and subsequent "rebound" hunger. By stabilizing these metabolic fluctuations, GLP-1s provide a steady state of fullness. Clinical trials from the last five years have shown that patients using these medications can lose between 10% and 15% of their body weight when combined with lifestyle modifications.
As a specialist in clinical lipidology, Dr. Jeereddy emphasizes that GLP-1s do more than just reduce calorie intake; they improve how the body processes energy. These medications stimulate the pancreas to release the right amount of insulin when blood sugar levels are high.
Research shared by the Cleveland Clinic highlights that GLP-1s also reduce the liver's production of glucagon, a hormone that raises blood sugar. This dual action improves insulin sensitivity and reduces systemic inflammation. For patients in Kenilworth, this means weight loss is often accompanied by improved cholesterol levels and lower blood pressure. If you are interested in learning how these biological tools can support your wellness journey, we encourage you to call Kenilworth Primary Care or visit our website to schedule an appointment.
